Physician profile
Chadd K Eaglin
NPI 1750599833
$490,026.54
in general payments reported to CMS, 2019-2025
27 companies · $253K in 2025
The $253K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,257 · 2020: $984 · 2021: $1,914 · 2022: $19K · 2023: $81K · 2024: $133K · 2025: $253K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $258K · Honoraria: $105K · Travel and Lodging: $44K · Consulting Fee: $41K · Food and Beverage: $19K · Education: $16.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $258,200.00 |
| Honoraria | $104,595.00 |
| Travel and Lodging | $44,290.69 |
| Consulting Fee | $41,400.00 |
| Food and Beverage | $18,629.65 |
| Education | $16.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $306,346.86 | 2021-2025 | Vraylar |
| Axsome Therapeutics, INC. | $173,523.96 | 2022-2025 | Auvelity, Sunosi |
| Otsuka America Pharmaceutical, INC. | $1,370.06 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,327.16 | 2021-2025 | Caplyta |
| Alkermes, INC. | $1,081.81 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Vanda Pharmaceuticals INC. | $1,008.68 | 2019-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $640.65 | 2019-2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $621.19 | 2019-2024 | Trintellix |
| Neuronetics, INC. | $582.96 | 2024 | Neurostar Tms Therapy System |
| Allergan, INC. | $549.76 | 2019-2020 | |
| Almatica Pharma LLC | $461.17 | 2022-2025 | Loreev Xr, Gralise |
| Sunovion Pharmaceuticals INC. | $435.33 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $417.49 | 2021-2025 | Qelbree, Qelbree |
| Idorsia Pharmaceuticals US INC | $351.30 | 2022-2024 | Quviviq |
| Tris Pharma INC | $297.62 | 2023-2024 | Dyanavel Xr, Quillichew Er, Quillivant |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $236.73 | 2019-2023 | Rexulti |
| Corium, LLC | $222.55 | 2022-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $137.32 | 2019-2020 | |
| Bausch Health US, LLC | $94.02 | 2019-2021 | |
| Neos Therapeutics, Lp | $86.46 | 2020-2025 | Adzenys Xr-Odt |
| Merck Sharp & Dohme LLC | $71.03 | 2020-2022 | |
| Eisai INC. | $60.46 | 2020-2022 | |
| Shire North American Group INC | $33.67 | 2019 | |
| Noven Pharmaceuticals, INC. | $23.71 | 2024 | Xelstrym |
| Noven Therapeutics, LLC | $18.53 | 2024 | Secuado, Xelstrym |
| Livanova USA, INC. | $14.89 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Alfasigma USA, INC. | $11.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chadd Eaglin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.